Literature DB >> 3499925

A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation.

M S Perelman1, W J McKenna, E Rowland, D M Krikler.   

Abstract

Fourteen patients with established atrial fibrillation (longer than three months) that was refractory to treatment were studied to compare the clinical and electrophysiological effects of amiodarone and bepridil. All patients initially received bepridil for three weeks (200-600 mg/day), followed by amiodarone for two to three months (100-400 mg/day). Bepridil seemed to be slightly more effective than amiodarone in converting the fibrillation to sinus rhythm (nine of fourteen compared with four of ten). The ventricular response in atrial fibrillation was equally well controlled by bepridil and amiodarone, both at rest and during exercise. Bepridil was associated with the development of ventricular arrhythmias in eight of fourteen patients; two had torsade de pointes, which in one degenerated into fatal ventricular fibrillation. These arrhythmias seemed to be associated with bepridil induced prolongation of the QTc interval. No ventricular arrhythmias were seen during amiodarone treatment. Although bepridil seems to be an effective antiarrhythmic agent for the management of atrial fibrillation, its arrhythmogenic actions make it unsuitable for this purpose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499925      PMCID: PMC1277264          DOI: 10.1136/hrt.58.4.339

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  9 in total

1.  [Bepridil and torsades de pointes].

Authors:  J F Leclercq; S Kural; P E Valère
Journal:  Arch Mal Coeur Vaiss       Date:  1983-03

2.  [A new antianginal drug, bepridil: efficacy estimation by exertion test during a double blind test against a placebo (author's transl)].

Authors:  J C Canicave; J Deu; J Jacq; R Paillet
Journal:  Therapie       Date:  1980 Sep-Oct       Impact factor: 2.070

3.  [Electrocardiographic changes induced by bepridil. A new calcium inhibitor].

Authors:  P Desoutter; R Haiat
Journal:  Arch Mal Coeur Vaiss       Date:  1980-10

4.  Some membrane interactions with bepridil, a new antianginal agent.

Authors:  C Labrid; A Grosset; G Dureng; J Mironneau; P Duchene-Marullaz
Journal:  J Pharmacol Exp Ther       Date:  1979-12       Impact factor: 4.030

5.  Blockade of myocardial slow channels by bepridil (CERM-1978).

Authors:  S Vogel; R Crampton; N Sperelakis
Journal:  J Pharmacol Exp Ther       Date:  1979-09       Impact factor: 4.030

6.  Studies on the bradycardia induced by bepridil.

Authors:  M Beaughard; M Ferrier; C Labrid; J C Lamar; J Leboeuf; P Piris
Journal:  Br J Pharmacol       Date:  1982-02       Impact factor: 8.739

7.  Bepridil for chronic stable angina pectoris: results of a prospective multicenter, placebo-controlled, dose-ranging study in 77 patients.

Authors:  R DiBianco; J Alpert; R J Katz; J Spann; E Chesler; D P Ferri; L J Larca; R B Costello; J M Gore; M J Eisenman
Journal:  Am J Cardiol       Date:  1984-01-01       Impact factor: 2.778

8.  Antidysrhythmic and electrophysiological effects of a new antianginal agent, bepridil.

Authors:  K A Kane; E Winslow
Journal:  J Cardiovasc Pharmacol       Date:  1980       Impact factor: 3.105

9.  Electrophysiologic and antiarrhythmic actions of bepridil. Comparison with verapamil and ajmaline for atrioventricular reentrant tachycardia.

Authors:  E Rowland; W J McKenna; D M Krikler
Journal:  Am J Cardiol       Date:  1985-06-01       Impact factor: 2.778

  9 in total
  8 in total

Review 1.  Rate Control in Atrial Fibrillation: Avoiding Morbidity.

Authors:  Thomas D Callahan
Journal:  J Atr Fibrillation       Date:  2012-12-16

2.  The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease.

Authors:  Lisa Evans DeWald; Julie Dyall; Jennifer M Sword; Lisa Torzewski; Huanying Zhou; Elena Postnikova; Erin Kollins; Isis Alexander; Robin Gross; Yu Cong; Dawn M Gerhardt; Reed F Johnson; Gene G Olinger; Michael R Holbrook; Lisa E Hensley; Peter B Jahrling
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

Review 3.  Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Antiarrhythmic and electrophysiological effects of SD-3212, a novel Na+ and Ca++ channel blocker, in anaesthetized dogs with myocardial infarction in comparison with its stereoisomer (SD-3211) and bepridil.

Authors:  S Nagashima; T Uematsu; S Araki; T Matsuzaki; M Fukuchi; H Hashimoto; M Nakashima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-06       Impact factor: 3.000

Review 5.  Calcium channel antagonists. Part V: Second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

6.  SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells.

Authors:  Y Hara; H Nakaya
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

Review 7.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18

Review 8.  The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations.

Authors:  S Nattel; T Hadjis; M Talajic
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.